Review

MintMed: a small monthly price can still carry an exit cost

Compare $89 and $119 monthly offers with prepaid totals, a 48-business-hour cancellation rule and the terms that apply before a prescription ships.

Editorial illustration of a magnifying glass and document; not a MintMed facility photograph

By Penny & Pound Editorial Team · Published 2026-10-15 · Public sources checked 2026-10-15


MintMed’s product pages advertise compounded semaglutide at $89 per month and tirzepatide at $119, including all doses under the company’s stated offer. Three- and six-month prepaid options reduce those monthly equivalents. For a cost-focused buyer, the less prominent detail is what happens when a subscription is canceled before the paid term ends.

This review uses public product pages, cancellation and refund policies, clinical disclosures and an FDA warning letter checked on October 15, 2026. We also opened the publicly linked cancellation form without entering or submitting information. We did not buy treatment, evaluate an individual prescription or verify the company’s clinical results.

The advertised annual budget, with assumptions visible

The semaglutide offer lists $89 billed monthly, $255 every three months and $480 every six months. The tirzepatide offer lists $119, $330 and $594 for those respective intervals. Multiplying the term charges produces the following twelve-month model, assuming unchanged rates and calendar-month terms.

Billing periodSemaglutide: payment / 12-month modelTirzepatide: payment / 12-month model
Monthly$89 / $1,068$119 / $1,428
Every three months$255 / $1,020$330 / $1,320
Every six months$480 / $960$594 / $1,188

Two six-month payments save $108 for semaglutide or $240 for tirzepatide against the twelve-monthly-payment model. Those are editorial calculations, not guaranteed future prices or tested invoices. A smaller saving can disappear if an exit adjustment applies. Compare the whole agreement before accepting a prepaid discount.

The same site carries a general $106-per-month banner, while these product cards show different amounts. We use the named treatment and selected term rather than assuming the banner describes every product. The pages also advertise a lifetime price lock, all-dose pricing and no membership or hidden fees, while noting that rate-lock and other terms apply. Obtain those conditions and any consultation charges in writing.

Cancellation is tied to processing, not delivery

The cancellation page and refund policy require the official form at least “48 business hours” before the next scheduled order processing date. That exact wording matters: it should not be shortened to two calendar days. Ask the company for the precise cutoff date, time and time zone for the next order.

The policy says orders cannot be canceled or refunded once processing begins, even if they have not shipped. A tracking number is therefore not the relevant cutoff. For someone considering a longer plan, the renewal date, processing date and pharmacy status all need to be recorded separately.

The cancellation page displays a malformed-looking address label, but its actual link opened a live Mint Med Cancellation Form during our read-only check. It asks for account details and a cancellation reason. We did not submit it, so this confirms discoverability of the form, not a successful cancellation or a processing time. Keep the submission and the company’s confirmation if you use it.

Early exit may change the prepaid discount

The subscription policy says some plans prepay three, six or twelve months. It says canceling before completion requires paying the difference between the promotional and full price to cover the balance. The public wording does not supply a worked calculation or a clear definition of the full price for every offer. Do not assume unused months will simply be refunded at the discounted equivalent.

Consultation fees become nonrefundable after a patient has been seen, except when the provider determines the patient is medically ineligible, according to the refund policy. The product page separately promises a refund if the patient is not eligible. Confirm the consultation amount, charge timing and exact declined-treatment refund before authorizing payment; the pages checked do not settle every billing detail.

Identify the business, clinician and pharmacy

The April 8, 2025 terms of service use MINT MED, LLC. The telehealth consent names Glow Medispa, LLC doing business as Mint Med, the same identity used in the FDA letter. These public descriptions should be reconciled in the agreement and receipt, rather than assuming the names represent interchangeable legal entities.

The trust and compliance page names Dr. Roderick Huff, MD, describes Elation Health for patient messaging and says compounded prescriptions are prepared by licensed 503A pharmacies. These are company disclosures; we did not independently audit licenses, security practices or an assigned pharmacy. Ask which clinical entity and dispensing pharmacy will handle your case.

The product page advertises 24-hour provider review with a business-hours footnote, free delivery in five to seven business days and a two-day cold-shipping label. Those statements address different stages, while 24/7 care-team language describes access rather than verified response performance. No shipping or support timings were tested. The site’s terms limit service to locations where its providers operate; do not infer eligibility from being able to open the website.

FDA history belongs beside the current disclosure

FDA’s June 8, 2026 warning letter, reference 730390, addressed to Glow Medispa, LLC dba Mint Med, describes a May 2026 website review. The agency found that Mint Med branding on pictured semaglutide and tirzepatide labels misleadingly suggested it was the compounder. The letter concerns those representations; it is not an independent test of the medicine a reader might receive.

The current product pages explicitly say Mint Med does not manufacture, compound or dispense medication, and that imagery is illustrative. That visible language does not establish that FDA has closed the matter; our reviewed sources do not confirm closure. FDA’s general guidance also explains that compounded GLP-1 products lack FDA approval and premarket review for safety, effectiveness and quality.

Our assessment: the product-specific payment totals are clear enough to model, but the processing deadline and early-exit adjustment can matter more than a modest prepaid saving. Read the Gimme Care review for another term-based offer, then compare annual and monthly commitments. Ask for a written total and cancellation calculation, not just a promise that the price stays low.

Sources and limits

Public sources support the dated additions. Company claims are not independent clinical evidence; no order, patient test or license audit was performed.

  1. MintMed semaglutide plans
  2. MintMed tirzepatide plans
  3. MintMed cancellation page
  4. MintMed refund policy
  5. MintMed subscription policy
  6. MintMed platform terms
  7. MintMed telehealth consent and operator
  8. MintMed clinical and pharmacy disclosures
  9. FDA warning letter to Glow Medispa dba Mint Med
  10. FDA concerns about unapproved GLP-1 drugs

Read next

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure